Bio Path Holdings Inc's ROI from its first quarter of 2026 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bio Path Holdings Inc's ROI in the first quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Bio Path Holdings Inc 's return on investment (ROI) in its first quarter of 2026

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Mar 31 2026) I. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Investment Change TTM	-	-	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	-8	-8	-8	-7	-3
Return On Investment (TTM)	-	-	-	-	-
BPTH's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-	-	-	-	-
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-9	-11	-12	-10	-10

BPTH Company Profile >> Back to BPTH Roi Comparisons >> See Annual BPTH Return On Investment

Return On Investment BPTH's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

News about Bio path Holdings inc Return on Investment ROI

Promising Advances in Advanced Solid Tumor Treatment BP1001-A Shows Early Efficacy in Phase 1/1b Clinical Trial

August 21, 2024

In a promising development for oncology, Bio-Path Holdings, Inc. has reported vital findings from its ongoing Phase 1/1b clinical trial of BP1001-A, a significant candidate for the treatment of advanced solid tumors. With the first patient receiving a second, higher dose of the trial drug, initial outcomes have revealed a noteworthy tumor reduction and stable disease status, supporting BP1001-A s potential as an effective therapeutic option.The recent responses observed underscore the innovative approach Bio-Path Holdings is taking in addressing the pressing need for new treatments in the oncology arena. As the lead investigator in the trial emphasizes, the early clinical experiences with BP1001-A highlight not only its safety profile but also potential efficacy, paving the way for future patient enrollment and treatment optimization.

Financial Statements
Bio Path Holdings Inc's I. Quarter Investments	$ -8 Millions	BPTH's Balance sheet
Bio Path Holdings Inc's I. Quarter Income	$ 0 Millions	Quarterly BPTH's Income Statement
BPTH's Income by Division		See BPTH's Income by Division

BPTH Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	1	1	14	26	15
Y / Y Investment Growth	-55.25 %	-90.8 %	-44.21 %	67.32 %	-28.53 %
Net Income in Millions	-10	-16	-14	-10	-11
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-1682.65 %	-1223.59 %	-97.07 %	-40.77 %	-71.1 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BPTH's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BPTH's Competitors
Subscribers only: Roi for Bio Path Holdings Inc's Suppliers
Subscribers only: Return On Investment for BPTH's Customers

Other Ratios
BPTH's Roa	BPTH's Inventory Turnover Ratio	BPTH's Growth Rates	BPTH's Dividend Statistics
	BPTH's Profitability Ratios	BPTH's Asset Turnover Ratio	BPTH's Dividend Growth
BPTH's Roe	BPTH's Valuation Ratios	BPTH's Financial Strength Ratios	BPTH's Dividend Payout Ratio

Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector	ROI
Elutia Inc	232.45 %
Silexion Therapeutics Corp	206.92 %
Kyntra Bio Inc	155.01 %
Arbutus Biopharma Corp	153.52 %
Rigel Pharmaceuticals Inc	132.72 %
Interpace Biosciences Inc	130.15 %
Oncotelic Therapeutics Inc	129.74 %
Coherus Oncology inc	128.80 %
Petros Pharmaceuticals inc	124.23 %
Quince Therapeutics Inc	114.14 %
Capforce Inc	102.27 %
Qhslab Inc	83.28 %
Advanced Biomed Inc.	81.85 %
Entera Bio Ltd	78.23 %
Pulmatrix Inc	77.85 %
Exelixis Inc	77.71 %
Ironwood Pharmaceuticals inc	72.86 %
Lensar Inc	71.13 %
Fortress Biotech Inc	70.93 %
Earth Science Tech Inc	68.75 %
Q32 Bio Inc	58.17 %
Oramed Pharmaceuticals Inc	54.33 %
Aurinia Pharmaceuticals Inc	54.02 %
Vaxart Inc	51.45 %
Escalon Medical Corp	51.07 %
Tg Therapeutics Inc	50.62 %
Zevra Therapeutics Inc	50.45 %
Idexx Laboratories Inc	50.05 %
Theravance Biopharma inc	43.85 %
Elite Pharmaceuticals Inc	43.22 %

Date modified: 2026-08-30T14:47:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.